Tufts University

Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months

Ovid, Axonis and others are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders

Plus: New CEOs at QuantX, Oak Hill, and updates from Every Cure, Mosaic, Anixa and more 

How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate

Plus: LNP company Hopewell emerges with $25M seed round and updates from Mozart, GSK, FibroGen and Deerfield

Models will not be implemented for years, industry will have chance to comment

Advisory committee says another non-mRNA vaccine is needed, expresses desire to encourage more COVID-19 vaccine development

Pharmaceutical companies balancing calls to disengage vs. duties to patients

BioCentury’s roundup of translational news